A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
Conditions: Allogeneic Stem Cell Transplantation Interventions: Drug: ASTX727; Drug: Donor Lymphocyte Infusion Sponsors: M.D. Anderson Cancer Center; Astex Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hematology | Oral Cancer | Research | Stem Cell Therapy | Stem Cells | Toxicology | Transplants